CHICAGO (GenomeWeb) – Flush with $50 million from a recent Series A investment from Japanese software giant NEC, biomedical software startup BostonGene plans to commercialize its technology for selecting the best therapies for cancer patients.
CHICAGO (GenomeWeb) – Flush with $50 million from a recent Series A investment from Japanese software giant NEC, biomedical software startup BostonGene plans to commercialize its technology for selecting the best therapies for cancer patients.
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.